Ligand Pharmaceuticals Inc. (LGND) Announces Presentation Of Positive Data From A Phase 1 Study On The Effect Of The SERM Lasofoxifene To Increase Testosterone Levels In Men
6/23/2014 8:28:43 AM
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago. The presentation provided data from a first-in-human clinical study of lasofoxifene that was performed by Pfizer and recently analyzed by Ligand demonstrating the potent and prolonged effect of a single dose to increase circulating testosterone and gonadotropin levels in healthy young men.
Help employers find you! Check out all the jobs and post your resume.
comments powered by